ArticleJournal of translational medicine2026
Mas receptor activation regulates the functional phenotype of myocardial macrophages through the Akt/Nrf2 signaling pathway to alleviate sepsis-induced cardiomyopathy.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Crosstalk between innate immune signaling pathways and integrated TLR, NLRP3 inflammasome, cGAS-STING, and NF-κB networks in sepsis.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundSepsis-induced cardiomyopathy (SIC) has high mortality due to uncontrolled cardiac inflammation and macrophage-mediated mitochondrial damage. The Ang-(1–7)/Mas receptor (MasR) axis exhibits anti-inflammatory effects, but its role in modulating macrophage phenotypes in SIC remains unclear. This study aimed to determine if MasR activation confers cardioprotective effects in SIC via the macrophage polarization-regulating Akt/Nrf2 pathway.
methodsBlood samples from healthy controls and patients with SIC were analyzed for MasR expression on monocytes via flow cytometry. SIC was induced in mice using the cecal ligation and puncture model, with pretreatment using the MasR agonist AVE0991. Cardiac macrophage-specific MasR overexpression was achieved using an AAV9 vector. Cardiac function, myocardial injury, macrophage phenotypes, mitochondrial morphology, and apoptosis were assessed by echocardiography, histopathology, transmission electron microscopy, TUNEL staining, and multiplex flow cytometry. Bone marrow-derived macrophages (BMDM) were exposed to LPS and treated with AVE0991 and the Nrf2 inhibitor ML385 in vitro. The role of the Akt/Nrf2 pathway in macrophage polarization and cardiomyocyte protection was confirmed through Western blot, flow cytometry, and a BMDM-H9c2 cardiomyocyte co-culture system.
resultsMasR expression on monocytes was significantly elevated in patients with SIC and correlated positively with IL-6, lactate, and TnI levels. In SIC mice, pretreatment with AVE0991 or cardiac macrophage-specific MasR overexpression significantly improved survival, enhanced cardiac function, and reduced myocardial injury and apoptosis. Mechanistically, MasR activation enhanced Akt phosphorylation and Nrf2 nuclear translocation in both myocardial tissue and BMDM, promoting a shift in cardiac macrophages from an inflammatory M1 state toward a protective M2 state, thereby reducing inflammatory infiltration. Additionally, MasR activation preserved mitochondrial homeostasis, enhancing mitochondrial membrane potential and ATP production. The Nrf2 inhibitor ML385 completely abolished the protective effects induced by AVE0991. In the co-culture system, conditioned medium from AVE0991-treated BMDM alleviated oxidative stress, mitochondrial damage, and apoptosis in H9c2 cells.
conclusionsMasR activation alleviates SIC by initiating the Akt/Nrf2 signaling axis, reprogramming cardiac macrophages towards a protective M2 phenotype, thereby reducing myocardial inflammation, enhancing mitochondrial function, and inhibiting cardiomyocyte apoptosis. This study suggests that targeting the MasR-Akt/Nrf2-macrophage axis may offer a novel therapeutic strategy for SIC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.